Evaluation of Vascular Endothelial Growth Factor as a Prognostic Marker for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast-Conserving Therapy
Purpose Vascular endothelial growth factor (VEGF) is an important protein involved in the process of angiogenesis that has been found to correlate with relapse-free and overall survival in breast cancer, predominantly in locally advanced and metastatic disease. A paucity of data is available on the...
Saved in:
Published in | International journal of radiation oncology, biology, physics Vol. 81; no. 5; pp. 1236 - 1243 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Elsevier Inc
01.12.2011
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Purpose Vascular endothelial growth factor (VEGF) is an important protein involved in the process of angiogenesis that has been found to correlate with relapse-free and overall survival in breast cancer, predominantly in locally advanced and metastatic disease. A paucity of data is available on the prognostic implications of VEGF in early-stage breast cancer; specifically, its prognostic value for local relapse after breast-conserving therapy (BCT) is largely unknown. The purpose of our study was to assess VEGF expression in a cohort of early-stage breast cancer patients treated with BCT and to correlate the clinical and pathologic features and outcomes with overexpression of VEGF. Methods and Materials After obtaining institutional review board approval, the paraffin specimens of 368 patients with early-stage breast cancer treated with BCT between 1975 and 2005 were constructed into tissue microarrays with twofold redundancy. The tissue microarrays were stained for VEGF and read by a trained pathologist, who was unaware of the clinical details, as positive or negative according the standard guidelines. The clinical and pathologic data, long-term outcomes, and results of VEGF staining were analyzed. Results The median follow-up for the entire cohort was 6.5 years. VEGF expression was positive in 56 (15%) of the 368 patients. Although VEGF expression did not correlate with age at diagnosis, tumor size, nodal status, histologic type, family history, estrogen receptor/progesterone receptor status, or HER-2 status, a trend was seen toward increased VEGF expression in the black cohort (26% black vs. 13% white, p = .068). Within the margin-negative cohort, VEGF did not predict for local relapse-free survival (RFS) (96% vs. 95%), nodal RFS (100% vs. 100%), distant metastasis-free survival (91% vs. 92%), overall survival (92% vs. 97%), respectively (all p >.05). Subset analysis revealed that VEGF was highly predictive of local RFS in node-positive, margin-negative patients (86% vs. 100%, p = .029) on univariate analysis, but it did not retain its significance on multivariate analysis (hazard ratio, 2.52; 95% confidence interval, 0.804–7.920, p = .113). No other subgroups were identified in which a correlation was found between VEGF expression and local relapse. Conclusion To our knowledge, our study is the first to assess the prognostic value of VEGF with the endpoint of local relapse in early-stage breast cancer treated with BCT, an important question given the recent increased use of targeted antiangiogenic agents in early-stage breast cancer. Our study results suggest that VEGF is not an independent predictor of local RFS after BCT, but additional, larger studies specifically analyzing the endpoint of VEGF and local relapse are warranted. |
---|---|
AbstractList | Purpose: Vascular endothelial growth factor (VEGF) is an important protein involved in the process of angiogenesis that has been found to correlate with relapse-free and overall survival in breast cancer, predominantly in locally advanced and metastatic disease. A paucity of data is available on the prognostic implications of VEGF in early-stage breast cancer; specifically, its prognostic value for local relapse after breast-conserving therapy (BCT) is largely unknown. The purpose of our study was to assess VEGF expression in a cohort of early-stage breast cancer patients treated with BCT and to correlate the clinical and pathologic features and outcomes with overexpression of VEGF. Methods and Materials: After obtaining institutional review board approval, the paraffin specimens of 368 patients with early-stage breast cancer treated with BCT between 1975 and 2005 were constructed into tissue microarrays with twofold redundancy. The tissue microarrays were stained for VEGF and read by a trained pathologist, who was unaware of the clinical details, as positive or negative according the standard guidelines. The clinical and pathologic data, long-term outcomes, and results of VEGF staining were analyzed. Results: The median follow-up for the entire cohort was 6.5 years. VEGF expression was positive in 56 (15%) of the 368 patients. Although VEGF expression did not correlate with age at diagnosis, tumor size, nodal status, histologic type, family history, estrogen receptor/progesterone receptor status, or HER-2 status, a trend was seen toward increased VEGF expression in the black cohort (26% black vs. 13% white, p = .068). Within the margin-negative cohort, VEGF did not predict for local relapse-free survival (RFS) (96% vs. 95%), nodal RFS (100% vs. 100%), distant metastasis-free survival (91% vs. 92%), overall survival (92% vs. 97%), respectively (all p >.05). Subset analysis revealed that VEGF was highly predictive of local RFS in node-positive, margin-negative patients (86% vs. 100%, p = .029) on univariate analysis, but it did not retain its significance on multivariate analysis (hazard ratio, 2.52; 95% confidence interval, 0.804-7.920, p = .113). No other subgroups were identified in which a correlation was found between VEGF expression and local relapse. Conclusion: To our knowledge, our study is the first to assess the prognostic value of VEGF with the endpoint of local relapse in early-stage breast cancer treated with BCT, an important question given the recent increased use of targeted antiangiogenic agents in early-stage breast cancer. Our study results suggest that VEGF is not an independent predictor of local RFS after BCT, but additional, larger studies specifically analyzing the endpoint of VEGF and local relapse are warranted. PURPOSEVascular endothelial growth factor (VEGF) is an important protein involved in the process of angiogenesis that has been found to correlate with relapse-free and overall survival in breast cancer, predominantly in locally advanced and metastatic disease. A paucity of data is available on the prognostic implications of VEGF in early-stage breast cancer; specifically, its prognostic value for local relapse after breast-conserving therapy (BCT) is largely unknown. The purpose of our study was to assess VEGF expression in a cohort of early-stage breast cancer patients treated with BCT and to correlate the clinical and pathologic features and outcomes with overexpression of VEGF.METHODS AND MATERIALSAfter obtaining institutional review board approval, the paraffin specimens of 368 patients with early-stage breast cancer treated with BCT between 1975 and 2005 were constructed into tissue microarrays with twofold redundancy. The tissue microarrays were stained for VEGF and read by a trained pathologist, who was unaware of the clinical details, as positive or negative according the standard guidelines. The clinical and pathologic data, long-term outcomes, and results of VEGF staining were analyzed.RESULTSThe median follow-up for the entire cohort was 6.5 years. VEGF expression was positive in 56 (15%) of the 368 patients. Although VEGF expression did not correlate with age at diagnosis, tumor size, nodal status, histologic type, family history, estrogen receptor/progesterone receptor status, or HER-2 status, a trend was seen toward increased VEGF expression in the black cohort (26% black vs. 13% white, p=.068). Within the margin-negative cohort, VEGF did not predict for local relapse-free survival (RFS) (96% vs. 95%), nodal RFS (100% vs. 100%), distant metastasis-free survival (91% vs. 92%), overall survival (92% vs. 97%), respectively (all p>.05). Subset analysis revealed that VEGF was highly predictive of local RFS in node-positive, margin-negative patients (86% vs. 100%, p=.029) on univariate analysis, but it did not retain its significance on multivariate analysis (hazard ratio, 2.52; 95% confidence interval, 0.804-7.920, p=.113). No other subgroups were identified in which a correlation was found between VEGF expression and local relapse.CONCLUSIONTo our knowledge, our study is the first to assess the prognostic value of VEGF with the endpoint of local relapse in early-stage breast cancer treated with BCT, an important question given the recent increased use of targeted antiangiogenic agents in early-stage breast cancer. Our study results suggest that VEGF is not an independent predictor of local RFS after BCT, but additional, larger studies specifically analyzing the endpoint of VEGF and local relapse are warranted. Vascular endothelial growth factor (VEGF) is an important protein involved in the process of angiogenesis that has been found to correlate with relapse-free and overall survival in breast cancer, predominantly in locally advanced and metastatic disease. A paucity of data is available on the prognostic implications of VEGF in early-stage breast cancer; specifically, its prognostic value for local relapse after breast-conserving therapy (BCT) is largely unknown. The purpose of our study was to assess VEGF expression in a cohort of early-stage breast cancer patients treated with BCT and to correlate the clinical and pathologic features and outcomes with overexpression of VEGF. After obtaining institutional review board approval, the paraffin specimens of 368 patients with early-stage breast cancer treated with BCT between 1975 and 2005 were constructed into tissue microarrays with twofold redundancy. The tissue microarrays were stained for VEGF and read by a trained pathologist, who was unaware of the clinical details, as positive or negative according the standard guidelines. The clinical and pathologic data, long-term outcomes, and results of VEGF staining were analyzed. The median follow-up for the entire cohort was 6.5 years. VEGF expression was positive in 56 (15%) of the 368 patients. Although VEGF expression did not correlate with age at diagnosis, tumor size, nodal status, histologic type, family history, estrogen receptor/progesterone receptor status, or HER-2 status, a trend was seen toward increased VEGF expression in the black cohort (26% black vs. 13% white, p=.068). Within the margin-negative cohort, VEGF did not predict for local relapse-free survival (RFS) (96% vs. 95%), nodal RFS (100% vs. 100%), distant metastasis-free survival (91% vs. 92%), overall survival (92% vs. 97%), respectively (all p>.05). Subset analysis revealed that VEGF was highly predictive of local RFS in node-positive, margin-negative patients (86% vs. 100%, p=.029) on univariate analysis, but it did not retain its significance on multivariate analysis (hazard ratio, 2.52; 95% confidence interval, 0.804-7.920, p=.113). No other subgroups were identified in which a correlation was found between VEGF expression and local relapse. To our knowledge, our study is the first to assess the prognostic value of VEGF with the endpoint of local relapse in early-stage breast cancer treated with BCT, an important question given the recent increased use of targeted antiangiogenic agents in early-stage breast cancer. Our study results suggest that VEGF is not an independent predictor of local RFS after BCT, but additional, larger studies specifically analyzing the endpoint of VEGF and local relapse are warranted. Vascular endothelial growth factor (VEGF) is an important protein involved in the process of angiogenesis that has been found to correlate with relapse-free and overall survival in breast cancer, predominantly in locally advanced and metastatic disease. A paucity of data is available on the prognostic implications of VEGF in early-stage breast cancer; specifically, its prognostic value for local relapse after breast-conserving therapy (BCT) is largely unknown. The purpose of our study was to assess VEGF expression in a cohort of early-stage breast cancer patients treated with BCT and to correlate the clinical and pathologic features and outcomes with overexpression of VEGF. After obtaining institutional review board approval, the paraffin specimens of 368 patients with early-stage breast cancer treated with BCT between 1975 and 2005 were constructed into tissue microarrays with twofold redundancy. The tissue microarrays were stained for VEGF and read by a trained pathologist, who was unaware of the clinical details, as positive or negative according the standard guidelines. The clinical and pathologic data, long-term outcomes, and results of VEGF staining were analyzed. The median follow-up for the entire cohort was 6.5 years. VEGF expression was positive in 56 (15%) of the 368 patients. Although VEGF expression did not correlate with age at diagnosis, tumor size, nodal status, histologic type, family history, estrogen receptor/progesterone receptor status, or HER-2 status, a trend was seen toward increased VEGF expression in the black cohort (26% black vs. 13% white, p = .068). Within the margin-negative cohort, VEGF did not predict for local relapse-free survival (RFS) (96% vs. 95%), nodal RFS (100% vs. 100%), distant metastasis-free survival (91% vs. 92%), overall survival (92% vs. 97%), respectively (all p >.05). Subset analysis revealed that VEGF was highly predictive of local RFS in node-positive, margin-negative patients (86% vs. 100%, p = .029) on univariate analysis, but it did not retain its significance on multivariate analysis (hazard ratio, 2.52; 95% confidence interval, 0.804–7.920, p = .113). No other subgroups were identified in which a correlation was found between VEGF expression and local relapse. To our knowledge, our study is the first to assess the prognostic value of VEGF with the endpoint of local relapse in early-stage breast cancer treated with BCT, an important question given the recent increased use of targeted antiangiogenic agents in early-stage breast cancer. Our study results suggest that VEGF is not an independent predictor of local RFS after BCT, but additional, larger studies specifically analyzing the endpoint of VEGF and local relapse are warranted. |
Author | Moran, Meena S., M.D Harris, Lyndsay, M.D Haffty, Bruce G., M.D Chung, Gina, M.D Yang, Qifeng, M.D., Ph.D Goyal, Sharad, M.D |
Author_xml | – sequence: 1 fullname: Moran, Meena S., M.D – sequence: 2 fullname: Yang, Qifeng, M.D., Ph.D – sequence: 3 fullname: Goyal, Sharad, M.D – sequence: 4 fullname: Harris, Lyndsay, M.D – sequence: 5 fullname: Chung, Gina, M.D – sequence: 6 fullname: Haffty, Bruce G., M.D |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25274243$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21093162$$D View this record in MEDLINE/PubMed https://www.osti.gov/biblio/22054461$$D View this record in Osti.gov |
BookMark | eNqFks2O0zAQgC20iP2BN0DIEkKcUuzYSZoLElTdBamIFVt-bpbrTFp3U7vYTlFfiOdkohSQuHCyNP7G45lvLsmZ8w4IecrZhDNevtpO7Db41X6SMwyxasIEf0Au-LSqM1EU387IBRMlywTC5-Qyxi1jjPNKPiLnOWe14GV-QX7OD7rrdbLeUd_SLzqavtOBzl3j0wY6qzt6E_yPtKHX2iQfqI5U09vg187HZA39oMM9BNri1cIbxD9Bp_cRqHV0rkN3zO6SXgN9G0DHRGfaGcRvsSS4FOkSwwka-tViiZHJZt5FCAfr1nS5gaD3x8fkYau7CE9O5xX5fD1fzt5li48372dvFpmRlUxZ3cq2bETVSGh0KacV5A2DsgLdgDACeFEa4LLVZtViAhN6tSrrGsQU06ZmKq7I8_HdoTcVjU1gNsY7ByapPGeFlCVH6uVI7YP_3kNMamejga7TDnwfVc1KXhS8qpCUI2mCjzFAq_bB7nQ4Ks7UoFFt1ahRDRoVqxRqxLRnpwL9agfNn6Tf3hB4cQJQmO7agFO18S9X5JXMpUDu9cgBDu1gIQw9ARpobBhaarz930_-fcB01lmseQ9HiFvfB4dCFFcxV0zdDSs3bBzHZavRgPgFggjWOg |
CODEN | IOBPD3 |
CitedBy_id | crossref_primary_10_1186_1477_7819_12_212 crossref_primary_10_1016_j_ijrobp_2013_05_052 crossref_primary_10_1016_j_jchromb_2012_06_004 crossref_primary_10_1177_147323001204000209 |
Cites_doi | 10.1007/s11060-004-4204-7 10.1158/1078-0432.CCR-06-1008 10.1158/1078-0432.CCR-0951-3 10.1093/annonc/mdi353 10.1016/0360-3016(90)90005-5 10.1038/sj.bjc.6690755 10.1200/JCO.2005.01.186 10.1002/cncr.20501 10.1016/j.ygyno.2006.09.031 10.1016/S0092-8674(00)81683-9 10.1007/s10549-005-9062-2 10.1016/j.breast.2008.02.010 10.1001/jama.295.21.2492 10.1007/s10456-005-9001-1 10.1002/(SICI)1096-9896(1998110)186:3<313::AID-PATH188>3.0.CO;2-X 10.1016/j.bbrc.2005.07.145 10.1126/science.1104819 10.1002/ijc.11662 10.1038/labinvest.3780204 10.1200/JCO.2000.18.10.2046 10.1200/JCO.2000.18.7.1423 10.1007/s12032-008-9157-9 10.1002/cncr.20500 10.1002/cncr.23881 10.1093/jnci/89.2.139 10.1634/theoncologist.5-suppl_1-37 10.1200/JCO.1998.16.9.3121 10.1158/1078-0432.CCR-08-0593 10.1016/j.ijrobp.2006.07.1379 10.1186/1471-2407-2-8 10.1093/annonc/mdp062 |
ContentType | Journal Article |
Copyright | Elsevier Inc. 2011 Elsevier Inc. 2015 INIST-CNRS Copyright © 2011 Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: Elsevier Inc. – notice: 2011 Elsevier Inc. – notice: 2015 INIST-CNRS – notice: Copyright © 2011 Elsevier Inc. All rights reserved. |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 OTOTI |
DOI | 10.1016/j.ijrobp.2010.07.031 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic OSTI.GOV |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-355X |
EndPage | 1243 |
ExternalDocumentID | 22054461 10_1016_j_ijrobp_2010_07_031 21093162 25274243 S0360301610009648 1_s2_0_S0360301610009648 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Independent Innovation Foundation of Shandong University grantid: 2009JQ007 – fundername: National Natural Science Foundation of China grantid: 30772133 – fundername: New Century Excellent Talents in University, Key Project of Chinese Ministry of Education grantid: 108080 – fundername: Yale University School of Medicine Department of Therapeutic Radiology Research Funds and the Breast Cancer Research Foundation |
GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 1B1 1P~ 1RT 1~5 29J 4.4 457 4G. 53G 5RE 5VS 7-5 AAEDT AAEDW AALRI AAQFI AAQQT AAQXK AAWTL AAXUO ABEFU ABJNI ABLJU ABNEU ABOCM ABUDA ACGFS ACIUM ADBBV ADMUD ADPAM ADVLN AENEX AEVXI AFCTW AFFNX AFJKZ AFRHN AFTJW AGRDE AHHHB AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN BELOY DU5 EBS EFJIC EJD F5P FDB FEDTE FGOYB FIRID G-2 GBLVA HED HMK HMO HVGLF HX~ HZ~ IHE J1W KOM LX3 M41 MO0 NQ- O9- OC~ OO- R2- RIG RNS ROL RPZ SAE SDG SEL SES SEW SSZ UDS UV1 X7M XH2 XPP Z5R ZGI ~S- AAIAV AGZHU AHPSJ ALXNB ZA5 08R AAUGY ABPTK IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 OTOTI |
ID | FETCH-LOGICAL-c474t-9f4f6d37d4eda6487e2d0e67eade3c3e156ce14facbf47403abb699e38f6d8c83 |
ISSN | 0360-3016 |
IngestDate | Fri May 19 00:47:23 EDT 2023 Fri Aug 16 08:43:30 EDT 2024 Thu Sep 26 17:08:17 EDT 2024 Sat Sep 28 07:58:42 EDT 2024 Sun Oct 22 16:06:23 EDT 2023 Fri Feb 23 02:26:52 EST 2024 Tue Oct 15 22:52:43 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Local relapse Molecular markers Breast cancer Breast-conserving therapy Vascular endothelial growth factor VEGF Human Relapse Breast disease Prognosis Genetic marker Biological marker Early stage Malignant tumor Molecular marker Mammary gland diseases Cancerology Vascular endothelium growth factor Treatment Breast Mammary gland Cancer |
Language | English |
License | CC BY 4.0 Copyright © 2011 Elsevier Inc. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c474t-9f4f6d37d4eda6487e2d0e67eade3c3e156ce14facbf47403abb699e38f6d8c83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 21093162 |
PQID | 906155177 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | osti_scitechconnect_22054461 proquest_miscellaneous_906155177 crossref_primary_10_1016_j_ijrobp_2010_07_031 pubmed_primary_21093162 pascalfrancis_primary_25274243 elsevier_sciencedirect_doi_10_1016_j_ijrobp_2010_07_031 elsevier_clinicalkeyesjournals_1_s2_0_S0360301610009648 |
PublicationCentury | 2000 |
PublicationDate | 2011-12-01 |
PublicationDateYYYYMMDD | 2011-12-01 |
PublicationDate_xml | – month: 12 year: 2011 text: 2011-12-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | New York, NY |
PublicationPlace_xml | – name: New York, NY – name: United States |
PublicationTitle | International journal of radiation oncology, biology, physics |
PublicationTitleAlternate | Int J Radiat Oncol Biol Phys |
PublicationYear | 2011 |
Publisher | Elsevier Inc Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Elsevier |
References | Burstein, Chen, Parker (bib12) 2008; 14 Aldridge, Lennard, Williams (bib3) 2005; 335 Konecny, Meng, Untch (bib10) 2004; 10 Gasparini, Toi, Gion (bib8) 1997; 89 Gasparini, Toi, Miceli (bib15) 1999; 5 Hovinga, Stalpers, van Bree (bib22) 2005; 74 Carey, Perou, Livasy (bib33) 2006; 295 Jones, Kasl, Howe (bib31) 2004; 101 Rimm, Camp, Charette (bib27) 2001; 7 Gasparini (bib13) 2000; 5 Linderholm, Grankvist, Wilking (bib11) 2000; 18 Newman (bib32) 2004; 101 Pejavar, Wilson, Haffty (bib23) 2006; 66 Haffty, Fischer, Fischer (bib24) 1990; 19 Turley, Scott, Watts (bib28) 1998; 186 Smith, Smith, Carter (bib29) 2000; 18 Rini, Small (bib2) 2005; 23 Hefler, Mustea, Konsgen (bib4) 2007; 13 Linderholm, Bergqvist, Hellborg (bib18) 2009; 26 Available from Hanahan, Weinberg (bib1) 2000; 100 Lund, Høg, Olsen (bib21) 2004; 108 Jain (bib7) 2005; 307 Mylona, Alexandrou, Giannopoulou (bib19) 2007; 104 Santini, Vincenzi, Perrone (bib38) 2005; 16 Linderholm, Tavelin, Grankvist (bib14) 1998; 16 Wu, Saldana, Chillar (bib34) 2002; 20 Kostopoulos, Arapantoni-Dadioti, Gogas (bib39) 2006; 96 Linderholm, Hellborg, Johansson (bib17) Epub 2009 June 23 Taha FM, Zeeneldin AA, Helal AM, et al. Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer. Clin Biochem. In press. Linderholm, Gruvbreger-Saal, Fernö (bib16) 2008; 17 Manders, Sweep, Tjan-Heijnen (bib36) 2003; 9 Feng, Wang, Jiao (bib37) 2002; 2 Ferrara, LeCouter, Lin (bib6) 2004; 1654 Moran, Yang, Harris (bib25) 2008; 113 Linderholm, Tavelin, Grankvist (bib35) 1999; 81 . Ramakrishnan, Subramanian, Yokoyama (bib5) 2005; 8 Foekens, Peters, Grebenchtchikov (bib9) 2001; 61 Camp, Charette, Rimm (bib26) 2000; 80 Toi, Inada, Hoshina (bib30) 1995; 1 Linderholm (10.1016/j.ijrobp.2010.07.031_bib11) 2000; 18 Jones (10.1016/j.ijrobp.2010.07.031_bib31) 2004; 101 Hovinga (10.1016/j.ijrobp.2010.07.031_bib22) 2005; 74 Rini (10.1016/j.ijrobp.2010.07.031_bib2) 2005; 23 Newman (10.1016/j.ijrobp.2010.07.031_bib32) 2004; 101 Gasparini (10.1016/j.ijrobp.2010.07.031_bib8) 1997; 89 Gasparini (10.1016/j.ijrobp.2010.07.031_bib15) 1999; 5 Foekens (10.1016/j.ijrobp.2010.07.031_bib9) 2001; 61 Manders (10.1016/j.ijrobp.2010.07.031_bib36) 2003; 9 Burstein (10.1016/j.ijrobp.2010.07.031_bib12) 2008; 14 Hefler (10.1016/j.ijrobp.2010.07.031_bib4) 2007; 13 Feng (10.1016/j.ijrobp.2010.07.031_bib37) 2002; 2 Toi (10.1016/j.ijrobp.2010.07.031_bib30) 1995; 1 Aldridge (10.1016/j.ijrobp.2010.07.031_bib3) 2005; 335 Jain (10.1016/j.ijrobp.2010.07.031_bib7) 2005; 307 Ferrara (10.1016/j.ijrobp.2010.07.031_bib6) 2004; 1654 Linderholm (10.1016/j.ijrobp.2010.07.031_bib17) 2009 Carey (10.1016/j.ijrobp.2010.07.031_bib33) 2006; 295 Turley (10.1016/j.ijrobp.2010.07.031_bib28) 1998; 186 10.1016/j.ijrobp.2010.07.031_bib20 10.1016/j.ijrobp.2010.07.031_bib42 Haffty (10.1016/j.ijrobp.2010.07.031_bib24) 1990; 19 Linderholm (10.1016/j.ijrobp.2010.07.031_bib16) 2008; 17 Santini (10.1016/j.ijrobp.2010.07.031_bib38) 2005; 16 Moran (10.1016/j.ijrobp.2010.07.031_bib25) 2008; 113 Smith (10.1016/j.ijrobp.2010.07.031_bib29) 2000; 18 Mylona (10.1016/j.ijrobp.2010.07.031_bib19) 2007; 104 Hanahan (10.1016/j.ijrobp.2010.07.031_bib1) 2000; 100 Linderholm (10.1016/j.ijrobp.2010.07.031_bib35) 1999; 81 Kostopoulos (10.1016/j.ijrobp.2010.07.031_bib39) 2006; 96 Ramakrishnan (10.1016/j.ijrobp.2010.07.031_bib5) 2005; 8 Camp (10.1016/j.ijrobp.2010.07.031_bib26) 2000; 80 Konecny (10.1016/j.ijrobp.2010.07.031_bib10) 2004; 10 Linderholm (10.1016/j.ijrobp.2010.07.031_bib18) 2009; 26 Gasparini (10.1016/j.ijrobp.2010.07.031_bib13) 2000; 5 Linderholm (10.1016/j.ijrobp.2010.07.031_bib14) 1998; 16 Rimm (10.1016/j.ijrobp.2010.07.031_bib27) 2001; 7 Wu (10.1016/j.ijrobp.2010.07.031_bib34) 2002; 20 10.1016/j.ijrobp.2010.07.031_bib40 10.1016/j.ijrobp.2010.07.031_bib41 Lund (10.1016/j.ijrobp.2010.07.031_bib21) 2004; 108 Pejavar (10.1016/j.ijrobp.2010.07.031_bib23) 2006; 66 |
References_xml | – volume: 19 start-page: 859 year: 1990 end-page: 865 ident: bib24 article-title: Regional nodal irradiation in the conservative treatment of breast cancer publication-title: Int J Radiat Oncol Biol Phys contributor: fullname: Fischer – volume: 8 start-page: 169 year: 2005 end-page: 182 ident: bib5 article-title: Angiogenesis in normal and neoplastic ovaries publication-title: Angiogenesis contributor: fullname: Yokoyama – volume: 89 start-page: 139 year: 1997 end-page: 147 ident: bib8 article-title: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma publication-title: J Natl Cancer Inst contributor: fullname: Gion – volume: 13 start-page: 898 year: 2007 end-page: 901 ident: bib4 article-title: Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer publication-title: Clin Cancer Res contributor: fullname: Konsgen – year: Epub 2009 June 23 ident: bib17 article-title: Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer publication-title: Ann Oncol contributor: fullname: Johansson – volume: 81 start-page: 727 year: 1999 end-page: 732 ident: bib35 article-title: Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer? publication-title: Br J Cancer contributor: fullname: Grankvist – volume: 100 start-page: 57 year: 2000 end-page: 70 ident: bib1 article-title: The hallmarks of cancer publication-title: Cell contributor: fullname: Weinberg – volume: 18 start-page: 1423 year: 2000 end-page: 1431 ident: bib11 article-title: Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment publication-title: J Clin Oncol contributor: fullname: Wilking – volume: 5 start-page: 37 year: 2000 end-page: 44 ident: bib13 article-title: Prognostic value of vascular endothelial growth factor in breast cancer publication-title: Oncologist contributor: fullname: Gasparini – volume: 61 start-page: 5407 year: 2001 end-page: 5414 ident: bib9 article-title: High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer publication-title: Cancer Res contributor: fullname: Grebenchtchikov – volume: 104 start-page: 557 year: 2007 end-page: 563 ident: bib19 article-title: The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma publication-title: Gynecol Oncol contributor: fullname: Giannopoulou – volume: 2 start-page: 8 year: 2002 ident: bib37 article-title: Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: Correlation with clinical features publication-title: BMC Cancer contributor: fullname: Jiao – volume: 80 start-page: 1943 year: 2000 end-page: 1949 ident: bib26 article-title: Validation of tissue microarray technology in breast carcinoma publication-title: Lab Invest contributor: fullname: Rimm – volume: 16 start-page: 1847 year: 2005 end-page: 1848 ident: bib38 article-title: Vascular endothelial growth factor (VEGF) expression is not associated with prognosis in patients with radically resected ampullary carcinoma publication-title: Ann Oncol contributor: fullname: Perrone – volume: 113 start-page: 2565 year: 2008 end-page: 2574 ident: bib25 article-title: Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer publication-title: Cancer contributor: fullname: Harris – volume: 307 start-page: 58 year: 2005 end-page: 62 ident: bib7 article-title: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy publication-title: Science contributor: fullname: Jain – volume: 18 start-page: 2046 year: 2000 end-page: 2052 ident: bib29 article-title: Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma publication-title: J Clin Oncol contributor: fullname: Carter – volume: 26 start-page: 480 year: 2009 end-page: 490 ident: bib18 article-title: Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor publication-title: Med Oncol contributor: fullname: Hellborg – volume: 9 start-page: 6363 year: 2003 end-page: 6370 ident: bib36 article-title: Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients publication-title: Clin Cancer Res contributor: fullname: Tjan-Heijnen – volume: 14 start-page: 7871 year: 2008 end-page: 7877 ident: bib12 article-title: VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy publication-title: Clin Cancer Res contributor: fullname: Parker – volume: 295 start-page: 2492 year: 2006 end-page: 2503 ident: bib33 article-title: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer study publication-title: JAMA contributor: fullname: Livasy – volume: 17 start-page: 484 year: 2008 end-page: 491 ident: bib16 article-title: Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer publication-title: Breast contributor: fullname: Fernö – volume: 96 start-page: 251 year: 2006 end-page: 261 ident: bib39 article-title: Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy publication-title: Breast Cancer Res Treatm contributor: fullname: Gogas – volume: 186 start-page: 313 year: 1998 end-page: 318 ident: bib28 article-title: Expression of VEGF in routinely fixed material using a new monoclonal publication-title: J Pathol contributor: fullname: Watts – volume: 20 start-page: 509 year: 2002 end-page: 516 ident: bib34 article-title: Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment publication-title: Int J Oncol contributor: fullname: Chillar – volume: 101 start-page: 1293 year: 2004 end-page: 1301 ident: bib31 article-title: African-American/white differences in breast carcinoma: p53 alterations and other tumor characteristics publication-title: Cancer contributor: fullname: Howe – volume: 66 start-page: 1320 year: 2006 end-page: 1327 ident: bib23 article-title: Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS+RT) publication-title: Int J Radiat Oncol Biol Phys contributor: fullname: Haffty – volume: 108 start-page: 833 year: 2004 end-page: 838 ident: bib21 article-title: Differential regulation of VEGF, HIF1alpha and angiopoietin-1, -2 and -4 by hypoxia and ionizing radiation in human glioblastoma publication-title: Int J Cancer contributor: fullname: Olsen – volume: 1 start-page: 961 year: 1995 end-page: 964 ident: bib30 article-title: Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer publication-title: Clin Cancer Res contributor: fullname: Hoshina – volume: 23 start-page: 1028 year: 2005 end-page: 1043 ident: bib2 article-title: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma publication-title: J Clin Oncol contributor: fullname: Small – volume: 1654 start-page: 69 year: 2004 end-page: 78 ident: bib6 article-title: EG-VEGF and Bv8: A novel family of tissue-restricted angiogenic factors publication-title: Biochim Biophys Acta contributor: fullname: Lin – volume: 16 start-page: 3121 year: 1998 end-page: 3128 ident: bib14 article-title: Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma publication-title: J Clin Oncol contributor: fullname: Grankvist – volume: 74 start-page: 99 year: 2005 end-page: 103 ident: bib22 article-title: Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines—A clue to radioresistance? publication-title: J Neurooncol contributor: fullname: van Bree – volume: 335 start-page: 793 year: 2005 end-page: 798 ident: bib3 article-title: Vascular endothelial growth factor receptors in osteoclast differentiation and function publication-title: Biochem Biophys Res Commun contributor: fullname: Williams – volume: 10 start-page: 1706 year: 2004 end-page: 1716 ident: bib10 article-title: Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients publication-title: Clin Cancer Res contributor: fullname: Untch – volume: 5 start-page: 101 year: 1999 end-page: 111 ident: bib15 article-title: Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy publication-title: Cancer J Sci Am contributor: fullname: Miceli – volume: 101 start-page: 1261 year: 2004 end-page: 1263 ident: bib32 article-title: Breast carcinoma in African-American and white women: Application of molecular biology to understand outcome disparities publication-title: Cancer contributor: fullname: Newman – volume: 7 start-page: 24 year: 2001 end-page: 31 ident: bib27 article-title: Tissue microarray: A new technology for amplification of tissue resources publication-title: Cancer J contributor: fullname: Charette – volume: 74 start-page: 99 year: 2005 ident: 10.1016/j.ijrobp.2010.07.031_bib22 article-title: Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines—A clue to radioresistance? publication-title: J Neurooncol doi: 10.1007/s11060-004-4204-7 contributor: fullname: Hovinga – volume: 13 start-page: 898 year: 2007 ident: 10.1016/j.ijrobp.2010.07.031_bib4 article-title: Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-1008 contributor: fullname: Hefler – ident: 10.1016/j.ijrobp.2010.07.031_bib20 – ident: 10.1016/j.ijrobp.2010.07.031_bib41 – volume: 7 start-page: 24 year: 2001 ident: 10.1016/j.ijrobp.2010.07.031_bib27 article-title: Tissue microarray: A new technology for amplification of tissue resources publication-title: Cancer J contributor: fullname: Rimm – volume: 10 start-page: 1706 year: 2004 ident: 10.1016/j.ijrobp.2010.07.031_bib10 article-title: Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-0951-3 contributor: fullname: Konecny – volume: 9 start-page: 6363 year: 2003 ident: 10.1016/j.ijrobp.2010.07.031_bib36 article-title: Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients publication-title: Clin Cancer Res contributor: fullname: Manders – volume: 1654 start-page: 69 year: 2004 ident: 10.1016/j.ijrobp.2010.07.031_bib6 article-title: EG-VEGF and Bv8: A novel family of tissue-restricted angiogenic factors publication-title: Biochim Biophys Acta contributor: fullname: Ferrara – volume: 16 start-page: 1847 year: 2005 ident: 10.1016/j.ijrobp.2010.07.031_bib38 article-title: Vascular endothelial growth factor (VEGF) expression is not associated with prognosis in patients with radically resected ampullary carcinoma publication-title: Ann Oncol doi: 10.1093/annonc/mdi353 contributor: fullname: Santini – volume: 19 start-page: 859 year: 1990 ident: 10.1016/j.ijrobp.2010.07.031_bib24 article-title: Regional nodal irradiation in the conservative treatment of breast cancer publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/0360-3016(90)90005-5 contributor: fullname: Haffty – volume: 81 start-page: 727 year: 1999 ident: 10.1016/j.ijrobp.2010.07.031_bib35 article-title: Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer? publication-title: Br J Cancer doi: 10.1038/sj.bjc.6690755 contributor: fullname: Linderholm – volume: 23 start-page: 1028 year: 2005 ident: 10.1016/j.ijrobp.2010.07.031_bib2 article-title: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma publication-title: J Clin Oncol doi: 10.1200/JCO.2005.01.186 contributor: fullname: Rini – volume: 101 start-page: 1261 year: 2004 ident: 10.1016/j.ijrobp.2010.07.031_bib32 article-title: Breast carcinoma in African-American and white women: Application of molecular biology to understand outcome disparities publication-title: Cancer doi: 10.1002/cncr.20501 contributor: fullname: Newman – volume: 104 start-page: 557 year: 2007 ident: 10.1016/j.ijrobp.2010.07.031_bib19 article-title: The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2006.09.031 contributor: fullname: Mylona – volume: 61 start-page: 5407 year: 2001 ident: 10.1016/j.ijrobp.2010.07.031_bib9 article-title: High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer publication-title: Cancer Res contributor: fullname: Foekens – volume: 100 start-page: 57 year: 2000 ident: 10.1016/j.ijrobp.2010.07.031_bib1 article-title: The hallmarks of cancer publication-title: Cell doi: 10.1016/S0092-8674(00)81683-9 contributor: fullname: Hanahan – volume: 96 start-page: 251 year: 2006 ident: 10.1016/j.ijrobp.2010.07.031_bib39 article-title: Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy publication-title: Breast Cancer Res Treatm doi: 10.1007/s10549-005-9062-2 contributor: fullname: Kostopoulos – volume: 17 start-page: 484 year: 2008 ident: 10.1016/j.ijrobp.2010.07.031_bib16 article-title: Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer publication-title: Breast doi: 10.1016/j.breast.2008.02.010 contributor: fullname: Linderholm – volume: 295 start-page: 2492 year: 2006 ident: 10.1016/j.ijrobp.2010.07.031_bib33 article-title: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer study publication-title: JAMA doi: 10.1001/jama.295.21.2492 contributor: fullname: Carey – volume: 8 start-page: 169 year: 2005 ident: 10.1016/j.ijrobp.2010.07.031_bib5 article-title: Angiogenesis in normal and neoplastic ovaries publication-title: Angiogenesis doi: 10.1007/s10456-005-9001-1 contributor: fullname: Ramakrishnan – volume: 186 start-page: 313 year: 1998 ident: 10.1016/j.ijrobp.2010.07.031_bib28 article-title: Expression of VEGF in routinely fixed material using a new monoclonal publication-title: J Pathol doi: 10.1002/(SICI)1096-9896(1998110)186:3<313::AID-PATH188>3.0.CO;2-X contributor: fullname: Turley – volume: 335 start-page: 793 year: 2005 ident: 10.1016/j.ijrobp.2010.07.031_bib3 article-title: Vascular endothelial growth factor receptors in osteoclast differentiation and function publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2005.07.145 contributor: fullname: Aldridge – ident: 10.1016/j.ijrobp.2010.07.031_bib42 – volume: 307 start-page: 58 year: 2005 ident: 10.1016/j.ijrobp.2010.07.031_bib7 article-title: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy publication-title: Science doi: 10.1126/science.1104819 contributor: fullname: Jain – volume: 5 start-page: 101 year: 1999 ident: 10.1016/j.ijrobp.2010.07.031_bib15 article-title: Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy publication-title: Cancer J Sci Am contributor: fullname: Gasparini – volume: 20 start-page: 509 year: 2002 ident: 10.1016/j.ijrobp.2010.07.031_bib34 article-title: Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment publication-title: Int J Oncol contributor: fullname: Wu – ident: 10.1016/j.ijrobp.2010.07.031_bib40 – volume: 108 start-page: 833 year: 2004 ident: 10.1016/j.ijrobp.2010.07.031_bib21 article-title: Differential regulation of VEGF, HIF1alpha and angiopoietin-1, -2 and -4 by hypoxia and ionizing radiation in human glioblastoma publication-title: Int J Cancer doi: 10.1002/ijc.11662 contributor: fullname: Lund – volume: 80 start-page: 1943 year: 2000 ident: 10.1016/j.ijrobp.2010.07.031_bib26 article-title: Validation of tissue microarray technology in breast carcinoma publication-title: Lab Invest doi: 10.1038/labinvest.3780204 contributor: fullname: Camp – volume: 18 start-page: 2046 year: 2000 ident: 10.1016/j.ijrobp.2010.07.031_bib29 article-title: Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma publication-title: J Clin Oncol doi: 10.1200/JCO.2000.18.10.2046 contributor: fullname: Smith – volume: 18 start-page: 1423 year: 2000 ident: 10.1016/j.ijrobp.2010.07.031_bib11 article-title: Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment publication-title: J Clin Oncol doi: 10.1200/JCO.2000.18.7.1423 contributor: fullname: Linderholm – volume: 26 start-page: 480 year: 2009 ident: 10.1016/j.ijrobp.2010.07.031_bib18 article-title: Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor publication-title: Med Oncol doi: 10.1007/s12032-008-9157-9 contributor: fullname: Linderholm – volume: 101 start-page: 1293 year: 2004 ident: 10.1016/j.ijrobp.2010.07.031_bib31 article-title: African-American/white differences in breast carcinoma: p53 alterations and other tumor characteristics publication-title: Cancer doi: 10.1002/cncr.20500 contributor: fullname: Jones – volume: 113 start-page: 2565 year: 2008 ident: 10.1016/j.ijrobp.2010.07.031_bib25 article-title: Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer publication-title: Cancer doi: 10.1002/cncr.23881 contributor: fullname: Moran – volume: 89 start-page: 139 year: 1997 ident: 10.1016/j.ijrobp.2010.07.031_bib8 article-title: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma publication-title: J Natl Cancer Inst doi: 10.1093/jnci/89.2.139 contributor: fullname: Gasparini – volume: 5 start-page: 37 year: 2000 ident: 10.1016/j.ijrobp.2010.07.031_bib13 article-title: Prognostic value of vascular endothelial growth factor in breast cancer publication-title: Oncologist doi: 10.1634/theoncologist.5-suppl_1-37 contributor: fullname: Gasparini – volume: 16 start-page: 3121 year: 1998 ident: 10.1016/j.ijrobp.2010.07.031_bib14 article-title: Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma publication-title: J Clin Oncol doi: 10.1200/JCO.1998.16.9.3121 contributor: fullname: Linderholm – volume: 14 start-page: 7871 year: 2008 ident: 10.1016/j.ijrobp.2010.07.031_bib12 article-title: VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-0593 contributor: fullname: Burstein – volume: 66 start-page: 1320 year: 2006 ident: 10.1016/j.ijrobp.2010.07.031_bib23 article-title: Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS+RT) publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2006.07.1379 contributor: fullname: Pejavar – volume: 2 start-page: 8 year: 2002 ident: 10.1016/j.ijrobp.2010.07.031_bib37 article-title: Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: Correlation with clinical features publication-title: BMC Cancer doi: 10.1186/1471-2407-2-8 contributor: fullname: Feng – year: 2009 ident: 10.1016/j.ijrobp.2010.07.031_bib17 article-title: Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdp062 contributor: fullname: Linderholm – volume: 1 start-page: 961 year: 1995 ident: 10.1016/j.ijrobp.2010.07.031_bib30 article-title: Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer publication-title: Clin Cancer Res contributor: fullname: Toi |
SSID | ssj0001174 |
Score | 2.1084535 |
Snippet | Purpose Vascular endothelial growth factor (VEGF) is an important protein involved in the process of angiogenesis that has been found to correlate with... Vascular endothelial growth factor (VEGF) is an important protein involved in the process of angiogenesis that has been found to correlate with relapse-free... PURPOSEVascular endothelial growth factor (VEGF) is an important protein involved in the process of angiogenesis that has been found to correlate with... Purpose: Vascular endothelial growth factor (VEGF) is an important protein involved in the process of angiogenesis that has been found to correlate with... |
SourceID | osti proquest crossref pubmed pascalfrancis elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1236 |
SubjectTerms | Adult African Continental Ancestry Group Aged Aged, 80 and over Analysis of Variance ANGIOGENESIS Biological and medical sciences Biomarkers, Tumor - analysis Breast cancer Breast Neoplasms - chemistry Breast Neoplasms - ethnology Breast Neoplasms - pathology Breast Neoplasms - therapy Breast-conserving therapy DIAGNOSIS Disease-Free Survival ESTROGENS European Continental Ancestry Group EVALUATION Female Follow-Up Studies GROWTH FACTORS Gynecology. Andrology. Obstetrics HAZARDS Hematology, Oncology and Palliative Medicine Humans Local relapse Mammary gland diseases MAMMARY GLANDS Mastectomy, Segmental Medical sciences METASTASES Middle Aged Molecular markers MULTIVARIATE ANALYSIS Neoplasm Recurrence, Local - chemistry Neoplasm Recurrence, Local - ethnology Neoplasm Recurrence, Local - pathology Neoplasm Staging NEOPLASMS PARAFFIN PATIENTS PROGESTERONE Prognosis Radiology RADIOLOGY AND NUCLEAR MEDICINE Radiotherapy RECEPTORS RECOMMENDATIONS THERAPY Tissue Array Analysis - methods Tumors Vascular endothelial growth factor Vascular Endothelial Growth Factor A - analysis VEGF |
Title | Evaluation of Vascular Endothelial Growth Factor as a Prognostic Marker for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast-Conserving Therapy |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0360301610009648 https://dx.doi.org/10.1016/j.ijrobp.2010.07.031 https://www.ncbi.nlm.nih.gov/pubmed/21093162 https://search.proquest.com/docview/906155177 https://www.osti.gov/biblio/22054461 |
Volume | 81 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5FqYS4IN4ESrUHbpEjP9avY1WlVLRFgqa0t5XX3m0TVU5kJ4fyg_iH3JnZXT9KW6BcrCjJOnHm884j33xDyAfpicRTuXDS2M8cpljhZJHLnDRXrghy9CBY0D_-HB2csk_n4flg8LPHWtqsxST_fmdfyf9YFZ4Du2KX7AMs254UnoDHYF84goXh-E82nrZS3RjzfWtIpdOywL6qKyyGf4Q0e3053tdjdXCoTIa9AciuQ6VW7NSRlaYaHqFT09y4Va2FRLT0sQPB6AUyCHDEz3gPIVKhrP9cN8bNMOKEiPUMi7nmPQ5OAMX9p7xANkerWLDoGPNdAbInW1GhRoK5kjJvO2hE10xjSjBtBnAM0DU0ZEjEs_HJpN2-bAH8y1xJ65W1_P-1nmxgBKqLbt-tKiOycHRdFrUlFBVtVbcjlDTNX-BOXNO22WzsidcDcNjbpVFxpufxIcQJ7vQmprCxmMwX1VKsLA8wnrjWb90Q7_7NqbZUx4ZFt-DmLBzPwt2Yu9j9v-XHaRgOydbu4dezwzaE8Kx8eHNVTc-nJibe_jb3xVRDxBKyfQF_2ZUyk1ruT6V0SDV7Sp7YXIjuGmA_IwNZPiePji3b4wX50eGbLhVt8E17-KYG39Tgm2Y1zWiHb2rwTQHfVOObWnzTeUl7-KYGu9Tgmzb4phbfFPFNb-GbWny_JKf709negWPnijg5i9naSRVTURHEBZNFFkHGLv3ClVGMvQNBHkgvjHLpMZXlQsECN8iEiNJUBgksS_IkeEWG5bKUbwiFcL0QCiPBIGFppAeEKJFJlJgQXuGOiNNYhq-MfAz_EyJGJG7Mx5vWaHDmsrY3ZM09Xvvc5SeIDYSGp6sQLOmvtMGzCYo5oPkvn7mNNsFVqBudI8EOlmEHPmMRvLxzAz_tdfgh0jxYMCK0ARQH34R_OGalXG5qnmK-FHpxPCKvDdC6xShj50X-2wf-QO_I4-7-3ybDdbWR7yEtWIsdexP9AlsAFMs |
link.rule.ids | 230,315,786,790,891,27955,27956 |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+Vascular+Endothelial+Growth+Factor+as+a+Prognostic+Marker+for+Local+Relapse+in+Early-Stage+Breast+Cancer+Patients+Treated+With+Breast-Conserving+Therapy&rft.jtitle=International+journal+of+radiation+oncology%2C+biology%2C+physics&rft.au=Moran%2C+Meena+S.&rft.au=Yang%2C+Qifeng&rft.au=Goyal%2C+Sharad&rft.au=Harris%2C+Lyndsay&rft.date=2011-12-01&rft.issn=0360-3016&rft.volume=81&rft.issue=5&rft.spage=1236&rft.epage=1243&rft_id=info:doi/10.1016%2Fj.ijrobp.2010.07.031&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_ijrobp_2010_07_031 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F03603016%2FS0360301611X00147%2Fcov150h.gif |